የአንጎል ዕጢዎችን ለማከም ለሊምፋማ ሉኪሚያ መድኃኒቶች

የኒው ክሊቭላንድ ክሊኒክ ጥናት ለመጀመሪያ ጊዜ እንደሚያሳየው በኤፍዲኤ ተቀባይነት ያለው ኢብሩቲኒብ (ኢብሩቲኒብ) ለሊምፎማ እና ሉኪሚያ በጣም የተለመዱ እና ገዳይ የሆኑ የአንጎል ዕጢዎችን ለማከም እንደሚረዳ እና አንድ ቀን glioblastoma ላለባቸው ታካሚዎች ጥቅም ላይ ሊውል ይችላል እና የመዳንን ፍጥነት ያሻሽላል።

የአሜሪካው የአዕምሮ እጢ ማኅበር ዘገባ እንደሚያመለክተው፣ የ glioblastoma በሕይወት የመትረፍ ፍጥነት በጣም ዝቅተኛ ነው፣ እና መደበኛ ሕክምና የሚያገኙ ታካሚዎች አማካይ ሕልውና ከ15 ወራት ያነሰ ነው። ግሊዮብላስቶማ በጣም ገዳይ የሆነው ዋና የአንጎል ዕጢ ሲሆን ለአሁኑ ሕክምናዎች በጣም የሚቋቋም ነው። እነዚህን ታካሚዎች በተቻለ ፍጥነት አዳዲስ ሕክምናዎችን ለማቅረብ አስቸኳይ ፍላጎት አለ.

In an earlier study, Bao and colleagues found that glioma stem cells contained high levels of a protein called BMX (bone marrow and X-linked non-receptor tyrosine kinase). BMX activates a protein called STAT3 (signal transduction and transcription activator 3), which is responsible for the invasive and tumorigenic properties of glioma stem cells. In this new study, the researchers found that ibrutinib works by inhibiting two proteins.

A research team led by Dr. Shideng Bao of the Cleveland Clinic Lerner Institute found that ibrutinib slowed the growth of brain እብጠቶች in a preclinical model and prolonged survival by more than 10 times that of existing standard chemotherapy drugs. Studies have found that ibrutinib works by inhibiting glioma stem cells, an aggressive brain cancer cell that tends to resist treatment and spread. In addition, combining ibrutinib with radiation therapy can prevent glioblastoma cells from developing drug resistance. Combination therapy is more effective than radiotherapy or ibrutinib alone in overcoming drug resistance and extending lifespan. Follow-up clinical trials are being carried out intensively, and we look forward to receiving FDA approval as soon as possible.

https://medicalxpress.com/news/2018-05-leukemia-lymphoma-drug-benefit-glioblastoma.html